This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Histone deacetylase (HDAC); interferon-g (IFNG; IFN-g)

Mouse studies suggest combining HDAC inhibitors with IFN-g stimulation may enhance antitumor efficacy. In immune-deficient mouse models of colon adenocarcinoma and lymphoma, an HDAC inhibitor had less potent antitumor activity than that seen in immunocompetent mice. In the lymphoma models, dual treatment with HDAC inhibitors and the Ifn-g-inducing agent a-GalCer increased survival compared with treatment using either agent alone. Next steps could include testing combined HDAC inhibition and immune stimulation in clinical trials.

SciBX 6(47); doi:10.1038/scibx.2013.1342
Published online Dec. 12, 2013

Patent and licensing status unavailable

West, A.C. et al. Cancer Res.; published online Oct. 24, 2013;
doi:10.1158/0008-5472.CAN-13-0890
Contact: Ricky W. Johnstone, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
e-mail:
ricky.johnstone@petermac.org